| Title: | Association of circulating immuno-oncology biomarkers with breast cancer risk: insights from two prospective cohorts |
| Journal: | npj Precision Oncology |
| Published: | 15 Jul 2025 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/40665092/ |
| DOI: | https://doi.org/10.1038/s41698-025-01019-z |
| URL: | https://www.nature.com/articles/s41698-025-01019-z.pdf |
Publication 16995
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Immuno-oncology biomarkers are promising tools for cancer risk assessment and early detection. To identify and validate their associations with breast cancer, nested case-control studies within the Taizhou Longitudinal Study (TZL) cohort and the UK biobank Pharma Proteomics Project (UKB-PPP) were conducted, comprising 195 and 881 incident breast cancer patients, together with their matched controls. Among the 92 plasma proteins tested by the Olink Immuno-oncology panel, 11 proteins were associated with breast cancer risk in the TZL cohort after multiple testing correction. Notably, hepatocyte growth factor (HGF) was validated in the UKB-PPP, particularly among postmenopausal women (OR = 1.13, 95% CI = 1.03-1.24). The association was stronger with Estrogen Receptor-negative breast cancer and confirmed by Mendelian Randomization analysis. Additionally, HGF mediated the effects of Healthy Lifestyle Index (27.17%) and BMI (19.79%) on breast cancer risk. Therefore, HGF could be an intervention target by either medicines or lifestyle changes to improve the prevention and treatment of breast cancer.</p>
10 Authors
- Jing Zheng
- Chen Suo
- Yan Wu
- Baokun Cao
- Ziyu Yuan
- Yanfeng Jiang
- Zhenqiu Liu
- Weimin Ye
- Haomin Yang
- Xingdong Chen
Enabling scientific discoveries that improve human health